Center for Andrology and Division of Endocrinology, The George Washington University, Washington, DC 20037, USA.
J Sex Med. 2011 Jun;8(6):1747-53. doi: 10.1111/j.1743-6109.2011.02255.x. Epub 2011 Mar 18.
Finasteride has been associated with reversible adverse sexual side effects in multiple randomized, controlled trials for the treatment of male pattern hair loss (MPHL). The Medicines and Healthcare Products Regulatory Agency of the United Kingdom and the Swedish Medical Products Agency have both updated their patient information leaflets to include a statement that "persistence of erectile dysfunction after discontinuation of treatment with Propecia has been reported in post-marketing use."
We sought to characterize the types and duration of persistent sexual side effects in otherwise healthy men who took finasteride for MPHL.
We conducted standardized interviews with 71 otherwise healthy men aged 21-46 years who reported the new onset of sexual side effects associated with the temporal use of finasteride, in which the symptoms persisted for at least 3 months despite the discontinuation of finasteride.
The types and duration of sexual dysfunction and the changes in perceived sexual frequency and sexual dysfunction score between pre- and post-finasteride use.
Subjects reported new-onset persistent sexual dysfunction associated with the use of finasteride: 94% developed low libido, 92% developed erectile dysfunction, 92% developed decreased arousal, and 69% developed problems with orgasm. The mean number of sexual episodes per month dropped and the total sexual dysfunction score increased for before and after finasteride use according to the Arizona Sexual Experience Scale (P<0.0001 for both). The mean duration of finasteride use was 28 months and the mean duration of persistent sexual side effects was 40 months from the time of finasteride cessation to the interview date. Study limitations include a post hoc approach, selection bias, recall bias for before finasteride data, and no serum hormone levels.
Physicians treating MPHL should discuss the potential risk of persistent sexual side effects associated with finasteride.
非那雄胺已被证明会导致多种随机对照试验中治疗男性型脱发(MPHL)的可逆不良性副作用。英国药品和保健品管理局(Medicines and Healthcare Products Regulatory Agency)和瑞典药品管理局(Swedish Medical Products Agency)均已更新其患者用药指南,在其中加入了一项声明,指出“在 Propecia 停药后的上市后使用中,已报告有勃起功能障碍持续存在的情况”。
我们旨在描述那些健康男性在因 MPHL 而使用非那雄胺后出现的持续性性副作用的类型和持续时间。
我们对 71 名年龄在 21-46 岁之间、因使用非那雄胺而出现新发与时间相关的性副作用的健康男性进行了标准化访谈,这些症状在停用非那雄胺后至少持续了 3 个月。
性障碍的类型和持续时间,以及在使用非那雄胺前后,对性频率和性障碍评分的感知变化。
研究对象报告了与使用非那雄胺相关的新发持续性性功能障碍:94%的人性欲降低,92%的人勃起功能障碍,92%的人性欲减退,69%的人出现性高潮障碍。根据亚利桑那性体验量表(Arizona Sexual Experience Scale),在使用非那雄胺前后,每月性活动次数减少,性障碍总评分增加(两者均 P<0.0001)。非那雄胺的平均使用时间为 28 个月,从停用非那雄胺到访谈日期,持续性性功能障碍的平均持续时间为 40 个月。研究局限性包括回顾性研究方法、选择偏倚、使用非那雄胺前数据的回忆偏倚,以及没有检测血清激素水平。
治疗 MPHL 的医生应讨论与非那雄胺相关的持续性性副作用的潜在风险。